DLD Asset Management LP Acquires New Holdings in ARK Genomic Revolution ETF $ARKG

DLD Asset Management LP bought a new position in shares of ARK Genomic Revolution ETF (BATS:ARKG) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 54,327 shares of the company’s stock, valued at approximately $1,509,000. DLD Asset Management LP owned about 0.12% of ARK Genomic Revolution ETF as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ARKG. Atlantic Union Bankshares Corp bought a new position in ARK Genomic Revolution ETF in the 2nd quarter valued at approximately $34,000. Strategic Wealth Investment Group LLC bought a new stake in ARK Genomic Revolution ETF during the 2nd quarter worth approximately $38,000. FWL Investment Management LLC increased its position in ARK Genomic Revolution ETF by 750.8% in the 2nd quarter. FWL Investment Management LLC now owns 2,765 shares of the company’s stock valued at $67,000 after acquiring an additional 2,440 shares during the period. Total Investment Management Inc. acquired a new position in ARK Genomic Revolution ETF in the 2nd quarter valued at approximately $70,000. Finally, NewEdge Advisors LLC raised its stake in shares of ARK Genomic Revolution ETF by 49.4% during the first quarter. NewEdge Advisors LLC now owns 5,384 shares of the company’s stock valued at $112,000 after acquiring an additional 1,780 shares during the last quarter.

ARK Genomic Revolution ETF Trading Down 2.3%

Shares of BATS:ARKG opened at $28.12 on Monday. The firm’s fifty day moving average is $30.20 and its 200-day moving average is $29.26. ARK Genomic Revolution ETF has a 52 week low of $17.50 and a 52 week high of $34.39.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.